Lucid Diagnostics (NASDAQ: LUCD) announced robust financial results for the fourth quarter and full year of 2024, highlighting significant growth in EsoGuard test volume and key strategic achievements. The company also provided a business update, emphasizing its progress in commercial coverage and new sales channels.
